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of rimonabant’s effects, showing that its beneﬁcial impact is
present even when accounting for any reductions in weight, sug-
gesting that there is an effect beyond weight loss.
OBESITY—Patient Reported Outcomes
POB5
THE IMPACT OF BODY MASS INDEX ON HEALTH-RELATED
QUALITY OF LIFE AMONG US ADULTS
Olesen AC, Liu GG, Chen SY
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
OBJECTIVES: To test the impact of body mass index (BMI) on
health-related quality of life (HRQOL) in overweight and obese
individuals. METHODS: Data were obtained from the 2002
Medical Expenditure Panel Survey (MEPS). MEPS collects data
on health care use, insurance, access, and satisfaction, along with
basic demographic and health status information for a repre-
sentative sample of the US civilian non-institutionalized popula-
tion. Our weighted sample consists of 207,969,360 adults.
Regression analyses were used to detect independent effects of
HRQOL (using EQ-5D US valuation and EQ VAS) on over-
weight and obese individuals. RESULTS: After adjusting for
com-morbidities, smoking status, and socio-demographic vari-
ables, respondents with a self-reported BMI >25.0kg/m2
reported impaired quality of life. Health-related quality of life
diminished with each increasing level of BMI (p < 0.01). Addi-
tionally, HRQOL signiﬁcantly diminished with increasing age 
(p < 0.01). CONCLUSIONS: Our ﬁndings suggest a signiﬁcant
impact of BMI on changes in HRQOL that is independent of 
co-morbidities and socio-demographic variables.
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SELF-IMAGE SCALE: A PRAGMATIC EVALUATION
Taieb C1, Schmitt C2, Bruel P3
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OBJECTIVES: To evaluate the self-image of women suffering
from overweight, using a validated questionnaire. METHODS:
Pharmacists who took part in this project gave 3 questionnaires
to all their customers who had purchased a cartane oil (80%
conjugated linoleic acids) treatment, explaining that the ﬁrst
questionnaire had to be ﬁlled in immediately after having bought
the product and theothers, after 6 and 10 weeks of treatment.
Once completed, the questionnaire had to be mailed in its pre-
paid envelop by the subject. Questionnaire were then collected,
typed in then analyzed anonymously. Self-image was evaluated
by BISS scale. The hereby analysis was obtained from the ﬁrst
118 ﬁlled in and returned questionnaires (inclusion, 6 & 10
weeks). The population was entirely made up of women with an
mean age of 43.5 years, mean weight of 67.6kg and average
height of 162cm. The BMI calculated using the two latter vari-
ables was of 25.5. RESULTS: For the SF-12 scale, mean scores
upon inclusion were respectively of 47.2 and 40.6 for the phys-
ical and mental dimension. Six weeks later, these same scores
were respectively of 45.6 and 45.6. Improvement is signiﬁcant
for the mental dimension. For the <<Self-image>> scale (BISS),
scores were 22.8 upon inclusion and 28.46 weeks later. The dif-
ference was signiﬁcant, hence putting forward an improvement
in the body’s image. After 10 weeks of treatment with cartane
oil the effect is sustained, self-image is signiﬁcantly improved
(33.1). CONCLUSIONS: This result is conﬁrmed through the
signiﬁcant improvement of the physical & mental dimension of
the SF-12. mean scores were respectively of 52.9 and 44.4 for
the physical and mental dimension.
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OBJECTIVES: To assess the impact of overweight/obesity on
health-related quality of life (HRQL) and health utility in the
U.S. METHODS: Adults (age >= 18) in the 2000 and 2002
Medical Expenditure Panel Survey (MEPS) were classiﬁed as
underweight (BMI < 18.5), normal weight (BMI: 18.5–24.9),
overweight (BMI: 25–29.9), obese (BMI: 30–39.9), and extreme
obese (BMI: >= 40). HRQL was measured using the SF-12
mental score and physical score. Underweight adults were
excluded form the analyses. Health utility was measured using
EQ-5D index score and visual analogue scale (EQ-VAS). A strat-
iﬁed matching method was used to compare overweight, obese,
and extreme obese samples with the corresponding normal
weight samples matched by age, gender, race, current smoking
status, and physical activity level. Effect sizes (ES) were esti-
mated. Bonferroni method was used to adjust for multiple com-
parisons. MEPS individual weights were applied to achieve
nationally representative statistics. RESULTS: Of the 36,897
adults in the study sample, 13,521 were with normal weight,
13,631 overweight, 8435 obese, and 1310 extremely obese.
Descriptive results showed that normal weight sample had the
highest average scores in all the HRQL and health utility mea-
sures. These ﬁndings were further supported by the results using
the stratiﬁed matching method. Compared to matching normal
weight adults, overweight adults had similar SF-12 mental scores
and EQ-VAS scores, but signiﬁcantly lower SF-12 physical scores
(ES = 6.24, p < 0.01) and EQ-5D index (ES = 3.72, p < 0.01).
On average, both obese and extremely obese adults had lower
SF-12 mental score (ES = 5.25 and 17.23, respectively), SF-12
physical score (ES = 23.78 and 60.04, respectively), EQ-5D index
(ES = 16.92 and 49.99, respectively), and EQ-VAS score (ES =
19.17 and 45.33, respectively). All differences were signiﬁcant at
1%. CONCLUSIONS: Our study showed that obesity is a con-
dition associated with signiﬁcant reduction of physical and
mental HRQL and health utility among adults in the United
States. Overweight had a negative impact on physical HRQL and
health utility.
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OBJECTIVES: To compare health-related quality of life
(HRQOL) using the Impact of Weight on Quality of Life-Lite
(IWQOL-Lite) questionnaire in subjects with or without abdom-
inal obesity (AO deﬁnition: waist circumference >102/88cm for
men/women, respectively). METHODS: Prospective Obesity
Cohort of Economic Evaluation and Determinants (PROCEED)
is an ongoing international, Internet-based, longitudinal, obser-
vational cohort of overweight/obese subjects [body mass index
(BMI) > or = 25kg/m2], aged 35–75, intending to lose weight.
The IWQOL-Lite is a validated 31-item self-reported question-
naire, speciﬁcally designed for HRQOL assessment in obesity,
and comprises 5 domains (Physical Function, Self-esteem, Sexual
Life, Public Distress, Work) and a total score. Using two-sample
t-tests, baseline IWQOL scores for USA subjects were compared
between AO groups overall; between genders within the sub-
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group with AO; and between AO groups within overweight sub-
group overall and within genders. RESULTS: Baseline analysis
was conducted in overweight/obese subjects (BMI > or =
25kg/m2) with AO (n = 674, male 42%, female 58%, mean age
50, 91% Caucasian) and without AO (n = 293, male 73%,
female 27%, mean age 50, 88% Caucasian). Overall, subjects
with AO reported a statistically signiﬁcantly (p < 0.05) lower
total score and lower scores in all 5 domains compared with sub-
jects without AO. In subjects with AO, women had statistically
signiﬁcant lower scores, for all domains and total score, com-
pared with men (p < 0.05). Overweight subjects (BMI 25–30
kg/m2) with AO (n = 220) also reported a statistically signiﬁ-
cantly (p < 0.05) lower total score compared with overweight
subjects without AO (n = 254), in the overall population, as well
as in women. In men, the only difference observed was in the
Physical Function score. CONCLUSION: AO was associated
with impaired HRQOL (assessed using the IWQOL-Lite) for
both men and women, with decreases for women being more
marked. The data obtained in this Internet-based cohort are con-
sistent with those from the literature.
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OBJECTIVES: To evaluate the impact of the ﬁrst selective
cannabinoid type 1 (CB1) receptor blocker, rimonabant, devel-
oped for the management of cardiometabolic risk factors, on
health related quality of life (HRQOL). METHODS: Over 6600
overweight/obese patients, with or without comorbidities were
randomized in double-blind, placebo-controlled, 2 ﬁxed doses (5
mg and 20mg), parallel-group clinical trials. Patients completed
the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) and
the Short-Form Health Survey (SF-36) questionnaires at baseline
and every 3 months up to 1 year. The IWQOL-Lite is a validated
31-item self-reported questionnaire speciﬁcally designed for
HRQOL assessment in obesity and comprises 5 domains and a
total score. SF-36 is a standardized generic HRQOL measure
used in general population (non-speciﬁc for obesity). Analyses
presented were performed on mean score changes from baseline
to 1 year in the intent-to-treat population. RESULTS: At 1 year,
patients administered rimonabant 20mg once daily reported
consistently greater improvement in IWQOL-Lite scores than
patients in the placebo group in all domains (Physical Function,
Self-esteem, Sexual Life, Public Distress, Work) and total score
(p < 0.001, except Work, p = 0.03). SF-36 provided statistically
signiﬁcant results for 5/8 domains (p < or = 0.05); 3 of them
(Physical Functioning, Bodily Pain, General Health) supported
greater improvement with rimonabant, while the other 2 (Role
Emotional and Mental Health) were less decreased with placebo.
Overall, HRQOL results appeared to be less clinically meaning-
ful on the SF-36 [effect sizes (ES) ranging between 0.01 and 0.33,
depending on the score considered] than on the IWQOL-Lite (ES
between 0.22 and 0.45). CONCLUSION: Using an obesity-
speciﬁc questionnaire (IWQOL-Lite), rimonabant 20mg was
associated with a signiﬁcant and sustained improvement in
HRQOL up to 1 year. As expected, SF-36 appeared to be less
sensitive to clinical changes in this overweight/obese population.
RESPIRATORY DISEASES—Clinical Outcomes Studies
PRS1
SURVIVAL AMONG COPD PATIENTS USING
FLUTICASONE/SALMETEROL IN COMBINATION VERSUS
OTHER INHALED STEROIDS AND BRONCHDIALATORS
ALONE
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OBJECTIVES: Recent studies have suggested that use of inhaled
corticosteroids (ICS) may improve survival in COPD, particularly
when combined with a long-acting beta agonist (LABA).
However, the methods used to conduct these retrospective studies
have been questioned and none have examined what effect the
newer combination ICS/LABA inhalers may have on survival. The
goal of this project was to further examine the relationship
between ICS treatment, with or without LABA, and survival in
COPD. METHODS: COPD patients were identiﬁed from the
administrative databases of four different managed care pro-
grams: Lovelace Health Plan (Albuquerque NM), Health Part-
ners Health System (Minneapolis/St Paul MN), Henry Ford
Health System’s Alliance Plan (Detroit MI), and Harvard Pilgrim
Health Care (Boston MA). All patients who were diagnosed with
COPD between September 1, 2000 and August 31, 2001 and who
had at least 3 months treatment with either ﬂuticasone/salmeterol
(ADVAIR, N = 866), some other ICS/LABA (N = 525), ICS alone
(N = 742), LABA alone (N = 531), or a short-acting bron-
chodilator alone (SABD, N = 1832), were included. RESULTS:
In the basic Cox proportional hazards models, use of ADVAIR,
ICS/LABA, and ICS alone had signiﬁcant survival beneﬁts as com-
pared to SABD alone, after adjustment for differences in age,
gender, comorbidities, asthma status, and disease severity (HRs
0.638, 0.603, and 0.784, respectively, p < 0.05). Propensity score
matching to reduce the clinical differences between the treatment
groups versus the SABD reference groups found very similar
results. Nested case-control matching based on survival status
continued to show a highly signiﬁcant survival beneﬁt for
ADVAIR; other treatments also had favorable RR that did not
reach statistical signiﬁcance. CONCLUSIONS: Treatment with
ADVAIR or another ICS with or without LABA is associated with
improved survival in COPD. The treatment beneﬁt seen with
ADVAIR is robust to a number of analyses designed to adjust for
differences in clinical parameters and bias by indication.
RESPIRATORY DISEASES—Cost Studies
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OBJECTIVES: Bronchodilators, including anticholinergics, are
central to the management of COPD. Current guidelines recom-
mend the use of bronchodilators in the management of mild to
moderate COPD and inhaled corticosteroids for severe patients
and patients with repeated exacerbations. This analysis evaluates
COPD patients treated with an inhaled corticosteroid or an anti-
cholinergic to determine the difference in treatment patterns and
costs between the two groups. METHODS: In a retrospective
database study, continuously enrolled patients aged 18 years and
older with a COPD diagnosis (COPD only or COPD+asthma),
